News & Updates

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.